hero image

Biogen Statement about Director and Chair of the Compensation and Management Development Committee Robert W. Pangia

June 2, 2021 Company Statements

Robert W. Pangia, who has served as a Biogen director since 1997, will retire from the company’s Board this year, effective at the annual meeting of stockholders. Biogen and the Board of Directors would like to thank Bob for his decades-long service and invaluable support.
 
In Bob’s nearly quarter-century tenure on the Biogen Board, he has supported the development of the company’s best-in-class governance principles, which have been critical to our success and to obtaining the trust and confidence of all our stakeholders. The Board has drawn upon Bob’s extensive financial and executive leadership experience during his time as Chair of the Compensation and Management Development Committee, leveraging his expertise to ensure and maintain the integrity of the company as we navigated life in the public domain.

With a background in healthcare investing and an entrepreneurial spirit, Bob has been attuned to the intricacies of our industry and well aligned with and supportive of our long-held mission of becoming a neuroscience pioneer that today discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. 

Bob has been an indispensable contributor to the Board and supported the company’s development through his wise counsel and active engagement. We are deeply grateful for his service and wish him the best for the future.
 

thumb
September 21, 2021
Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience

33 early and late-stage clinical programs across modalities and innovative discovery platforms Uniquely positioned to lead in Alzheimer’s disease with ADUHELM ® (aducanumab-avwa) and industry-leading pipeline including Phase 3 lecanemab Potential to transform standard of care in several areas of

thumb
September 20, 2021
FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)

BYOOVIZ™ becomes the first ophthalmology biosimilar to gain FDA approval in the United States INCHEON, Korea and CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S.